Harnessing protease activity to improve cancer care
Name
860cad3a58079dba381735ef0063071938e4.pdf
Description
Accepted version
Size
1.4 MB
Format
Adobe PDF
Checksum (MD5)
782a0b3745cc25c47864cafe18367510
Author(s)
Dudani, Jaideep S.
Warren, Andrew D.
Bhatia, Sangeeta N.
Date Issued
March 2018
Journal
Annual review of cancer biology
Publisher
Annual Reviews
Citation
Dudani, Jaideep S., Andrew D. Warren, and Sangeeta N. Bhatia, "Harnessing protease activity to improve cancer care." Annual review of cancer biology 2 (2018): p. 353-76 doi 10.1146/ANNUREV-CANCERBIO-030617-050549 ©2018 Author(s)
Version
Author's final manuscript
Abstract
Proteolysis plays critical roles in normal and pathologic physiology; these enzymes are intricately involved in cancer progression and spread. Our understanding of protease function has advanced from nonspecific degrading enzymes to a modern appreciation of their diverse roles in posttranslational modification and signaling in a complex microenvironment. This new understanding has led to next-generation diagnostics and therapeutics that exploit protease activity in cancer. For diagnostics, protease activity may be measured as a biomarker of cancer, with wide-ranging utility from early detection to monitoring therapeutic response. Therapeutically, while broad inhibition of protease activity proved disappointing, new approaches that more specifically modulate proteases in concert with secondary targets might enable potent combination therapies. In addition, clinical evaluation is underway for tools that leverage protease activity to activate therapeutics, ranging from imaging agents that monitor surgical margins to immunotherapies with improved specificity. Technologies that interact with, measure, or modulate proteases are poised to improve cancer management on diagnostic and therapeutic fronts to realize the promise of precision medicine. ©2018 Keywords: protease activity; degradomics; activity-based biomarkers; responsive nanomaterials; protease-targeted therapeutics; protease-triggered therapeutics
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1146/ANNUREV-CANCERBIO-030617-050549
